Tetrabenazine induces depression in animal models (2) . Depression has also been reported in 15% of patients under tetrabenazine treatment, with anxiety states in more than 10%. These side effects have been described as dose-related and usually abated after discontinuation of the drug (1) .
There are no data regarding risk factors for psychiatric side effects with this drug, nor are there any data on the efficacy of antidepressants in treating tetrabenazineinduced anxiodepressive states. Could prophylactic antidepressant treatment prevent their appearance? We describe here 2 cases illustrating psychiatric side effects.
Case Report 1
Mrs H is a 55-year-old secretary. She had Sydenham's chorea at age 3 years and developed subsequent tics. She suffered from a major depression in 1995, which was treated with sertraline and then venlafaxine 37.5 mg daily. In the neurologist's opinion, she suffered from Tourette syndrome. He stopped her antidepressant and began treatment with tetrabenazine 25 mg twice daily. After 6 weeks her tics improved, but she began to feel anxious and depressed. She described paralyzing terrors that made her unable to do most of her daily activities. She also described somatic worries and intensified agoraphobia. Tetrabenazine was withdrawn and paroxetine 25 mg daily was introduced. It was subsequently stopped because of side effects.
We saw her in psychiatric consultation 1 month after tetrabenazine washout. Because her anxiodepressive state remained unchanged, we introduced citalopram 20 mg daily. At the control visit 1 month later, she appeared less anxious. She described obsessive-compulsive symptoms that had been present for many years but that had clearly been increased by tetrabenazine and concomitant antidepressant withdrawal. We increased citalopram to 40 mg daily and added low-dose risperidone 0.75 mg daily. However, she finally improved only after a few months' trial of high-dose venlafaxine and continued risperidone treatment.
Case Report 2
The second case is a 40-year-old man with dystonia of the right foot related to a perinatal encephalopathy. After 1 month of tetrabenazine 150 mg daily treatment, he presented with irritability, insomnia, panic attacks, depressive and guilty thoughts, and obsessional ruminations. This state was attributed to tetrabenazine treatment because he had never before reported such symptoms. We stopped tetrabenazine and began treatment with sertraline 50 mg daily. This treatment rapidly alleviated the panic attacks and obsessionality, and his mood improved. Deficient monoaminergic states have been proposed as pathophysiological mechanisms underlying anxious and depressive disorders. Anxious and depressive symptoms have been linked to noradrenergic and serotonergic dysfunction (3) (4) (5) . This hypothesis is supported by the efficacy of serotonergic antidepressants in treating anxiety, depression, and obsessive-compulsive disorders (6) . The fact that a tryptophan-free diet also exacerbates anxiodepressive states in predisposed patients supports the monoaminergic depletion theory (7) . Our 2 patients had florid psychiatric symptoms precipitated or exacerbated by tetrabenazine (and in the first case, by a concomitant antidepressant withdrawal). We believe tetrabenazine treatment warrants careful psychiatric evaluation and follow-up. The target population for tetrabenazine treatment is probably at risk because of a high comorbid prevalence of psychiatric disorders. Future studies should explore the efficacy of prophylactic or curative antidepressant therapy for anxiodepressive states precipitated by tetrabenazine.
